60 results about "Mapk signaling pathway" patented technology

The invention belongs to the technical field of biological medicine, and particularly discloses application of kaempferol in preparation of a medicine for treating chronic obstructive pulmonary disease. The invention provides application of kaempferol in preparation of a medicine for treating chronic obstructive pulmonary disease. The invention provides a medicine for treating chronic obstructive pulmonary disease. The medicine comprises kaempferol or pharmaceutically acceptable salt thereof as an active ingredient. The invention aims to provide the application of kaempferol in preparation of the medicine for treating the chronic obstructive pulmonary disease, and the chronic obstructive pulmonary disease is treated by adjusting an AMPK signal channel, a Hippo signal channel, an MAPK signal channel and a PI3K-AKT signal channel.

The invention relates to the technical field of genetic engineering, in particular to a long-chain RNALnc012227 for inhibiting transmission of salmonella enteritidis ovary and application of the long-chain RNALnc012227 in prevention and control of salmonella enteritidis infection. The invention relates to a long-chain RNA (Ribonucleic Acid) Lnc012227 for inhibiting transmission of salmonella enteritidis ovary. The Lnc012227 provided by the invention can be used for indirectly regulating the expression of MAP3K8, activating NF-kappa B and MAPK signal channels and enhancing the inflammatory response of a host, so that S.Enteridis infection is controlled. The discovery not only provides a new understanding of molecular level for understanding the infection mechanism of salmonella in the duck body, but also provides a potential target spot for developing a new treatment strategy, and is helpful for reducing egg-laying duck ovarian infection and duck egg pollution caused by salmonella.

The invention belongs to the technical field of biological medicines, and particularly discloses application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. According to the application of the (E)-BCI hydrochloride in preparation of the medicine for treating sepsis, by inhibiting the activity of bispecific phosphatase 6, a mitogen activated protein kinase signal channel is regulated and controlled, and the expression level of inflammatory factors IL-1beta and TNF-alpha is reduced. The invention discloses application of (E)-BCI hydrochloride in preparation of drugs for treating sepsis, BCI enters from a new target for regulating inflammation and immune balance through a targeted DUSP6 / MAPK signal channel, a non-antibiotic-dependent drug is provided for treatment of sepsis, and the (E)-BCI hydrochloride is especially suitable for systemic inflammatory response syndromes caused by infection, operations, wounds and other inducements, and has a wide application prospect. Wide clinical application prospects are realized.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of FKBP10 in diagnosis and treatment of atherosclerosis. Specifically, the invention demonstrates that FKBP10 promotes the unique effect of EndMT in vascular pathology, which is associated with increasing the phenotypes of atherosclerosis and unstable plaques. The invention proves that FKBP10 promotes membrane localization of PARP1, activates PI3K / AKT and MAPK signal pathways, induces EndMT and promotes atherosclerosis and poor prognosis of patients. Meanwhile, EndMT is inhibited by screening a small molecule drug TAK733, and a new scheme is provided for clinical treatment of atherosclerosis, so that the application has good potential practical application value.

The invention provides an application of protocatechuic acid in an anti-inflammatory active pharmaceutical composition in dairy cow mammary epithelial cells, belongs to the technical field of bioengineering, and aims to obtain high-purity protocatechuic acid (greater than or equal to 95%) by optimizing a preparation process through the application of protocatechuic acid in inhibition of inflammatory response of dairy cow mammary epithelial cells. Under the concentration of 1-100 mu M, the level of inflammatory factors such as TNF-alpha, IL-6 and the like is remarkably reduced (the inhibition rate is larger than or equal to 60%), the mechanism is that NF-kB and MAPK signal channels are inhibited, cytotoxicity is avoided, and a milk region perfusion agent or a feed additive can be prepared to be used for preventing and treating dairy cow mastitis.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The invention discloses application of a kynurenase protein inhibitor in preparation of a medicine for treating radioactive intestinal injury, and belongs to the technical field of biological medicine. The invention discloses the interaction between the kynurenase protein KYNU and the radioactive intestinal injury for the first time, and through gene knockout and expression research of an MAPK signal channel, it is clear that the radioactive intestinal injury can be effectively relieved by inhibiting the expression of the KYNU. Based on the research results, the invention emphatically puts forward that carbidopa can be used as a kynureninase protein KYNU inhibitor and plays a key role in radioactive intestinal injury, so that a new medicine application for treating radioactive intestinal injury is provided aiming at KYNU inhibition; the invention also provides a small interfering RNA (siRNA) for inhibiting the expression of kynureninase protein KYNU for the first time, the KYNU is knocked down, so that the cell proliferation after irradiation can be increased, the cell apoptosis and oxidative stress can be reduced, and KYNU knock-down has a protective effect on radioactive intestinal injury.

The invention relates to an application of a bioactive peptide YPFPGPIH derived from bovine casein in the aspect of anti-inflammation or immunoregulation. The peptide can be combined with TLR2 and TLR4 to inhibit the activation of NF-kappa B and MAPK signal channels, so that the levels of inflammatory factors such as IL-1beta, TNF-alpha and NO are remarkably reduced, the expression of IL-10 is up-regulated, and inflammation balance regulation is realized; the body inflammatory response is improved, and the immune organ injury is recovered. The peptide can be used for preparing anti-inflammatory drugs, immunomodulatory functional foods and nutritional supplements, and has good safety and application prospects.

The invention provides an application of farrerol in preparation of a medicine for preventing osteoporotic diseases caused by inflammatory bowel diseases, and belongs to the technical field of inflammatory bone disease treatment.The application comprises the steps that firstly, an ulcerative colitis (UC) mouse is constructed to simulate occurrence of the osteoporosis induced by enteritis, and the occurrence of the osteoporosis induced by enteritis is simulated through microcomputer tomography (CT), hematoxylin and eosin (Hamp; e) and tartrate-resistant acid phosphatase (TRAP) staining are used for analyzing the bone destruction degree and the number of osteoclasts, and the influence of the farrerol on osteoclast generation and bone loss is detected. The influence of the farrerol on the inflammatory bowel disease is analyzed through 16S rRNA (ribosomal Ribonucleic Acid) sequencing. In addition, PI3K-AKT and MAPK signal pathways related to osteoclast differentiation of the farrerol are detected through WB and PCR experiments to clarify the basic molecular mechanism of the farrerol for preventing osteoporosis. Results show that the farrerol can improve bone loss caused by enteritis, recover intestinal flora composition and repair intestinal barriers.

The present application belongs to the technical field of precision medicine of tumors. Disclosed is the use of a TMED8 gene in the preparation of a drug for treating a tumor and a kit for diagnosing

The invention discloses an additive for resisting cow ovarian aging and its application. The additive is made of a composition of anthocyanidins, glycyrrhizic acid and wolfberry glycopeptide. When the composition is used in clinical veterinary treatment of cow ovarian aging, the role of primary cow ovarian granulosa cells is clarified through transcription, which is mainly involved in regulating programmed cell death, Ras protein signal transduction, tissue development, cell serine, tryptophan kinase activity, MAPK signaling pathway, PI3K-AKT signaling pathway, and laser confocal results show that the composition can significantly reduce the production of mitochondrial reactive oxygen; at the same time, the therapeutic effect on the persistent corpus luteum of the main cow is achieved by improving the intestinal flora structure, and more specifically, the colony is significantly changed upstream at the genus and species level; B-ultrasound results reveal that for a persistent corpus luteum cow, more large follicles can be detected on the ovaries after one month of gavage with the additive composition.

The present invention relates to the technical field of drug synthesis. Specifically, a six-membered lactam compound and a use thereof are provided, the compound having a structure represented by formula I, or stereoisomers, tautomers, racemates thereof, or pharmaceutically acceptable salts, esters, solvates, polymorphs, nitrogen oxides, isotope labels, metabolites, hydrates thereof, the structure represented by formula I being formula (I). The compound and a composition can be used to prepare an MEK or Ras-MAPK signaling pathway inhibitor, which has better activity, can fully inhibit the MEK or Ras-MAPK signaling pathway, and provides a new way to treat diseases related to the MEK or Ras-MAPK signaling pathway.

This invention discloses a coumarin compound and its uses, belonging to the field of chemical and pharmaceutical technology. This invention provides coumarin compounds represented by Formula I, particularly some specific coumarin compounds. These compounds and their compositions can inhibit the MEK or Ras-MAPK signaling pathway, providing a new approach for treating diseases related to the MEK or Ras-MAPK signaling pathway.

The invention discloses a pharmaceutical composition containing radix astragali, radix salviae miltiorrhizae, radix salviae miltiorrhizae and fructus schizandrae and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, the pharmaceutical composition containing radix astragali, radix salviae miltiorrhizae, radix salviae miltiorrhizae and fructus schizandrae is prepared from the following raw materials in parts by weight: 30-50 parts of radix astragali, 15-30 parts of radix salviae miltiorrhizae, 15-30 parts of radix codonopsis, 15-30 parts of radix pseudostellariae, 3-5 parts of fructus schizandrae and 10-15 parts of radix et rhizoma rhei. Preferably, the oral medicine dosage forms capable of being prepared comprise hard capsules, tablets and granules. According to the application disclosed by the invention, the expression levels of p38MAPK, JNK and ERK proteins, c-fos mRNA and c-jun mRNA of myocardial tissues of rats in a medicine group are lowest, so that the medicine disclosed by the invention can be used for inhibiting the activity of an MAPK signal channel of the myocardial tissues and inhibiting the expression of related protooncogenes c-fos and c-jun so as to inhibit myocardial fibrosis. Therefore, the medicine can effectively improve the cardiac function of a DCM model rat and relieve myocardial damage, and the effect of the medicine is related to inhibition of MAPK signal channel activity.

The present invention relates to the technical field of chemicals and pharmaceuticals. Disclosed are a coumarin compound and a use thereof. The present invention provides a coumarin compound represented by formula I, and some specific coumarin compounds. The compound and composition can effectively inhibit MEK or Ras-MAPK signaling pathways, can be used for preparing MEK or Ras-MAPK signaling pathway inhibitors, and provide a new way for treating MEK or Ras-MAPK signaling pathway-related diseases.

This invention relates to the field of plant disease biological control technology, and particularly to a Fusarium oxysporum cell wall extract, its preparation method, and its application. The extract is derived from the polysaccharide fraction of the cell wall of Fusarium oxysporum spores or hyphae, and contains at least one pathogen-associated molecular pattern (PAMP) component. This component is a non-protein, thermally stable, species-nonspecific elicitor capable of forming an aqueous dispersion system. The extract of this invention can be recognized by plant PRRs and activate PTI immunity. Rehmannia glutinosa tubers treated with the extract showed a significantly increased germination rate after inoculation with Fusarium oxysporum. It also induces superoxide anion production, upregulates the activities of superoxide dismutase, peroxidase, and catalase, and enriches differentially expressed genes in the MAPK signaling pathway, jasmonic acid metabolism pathway, and phenylpropane biosynthesis pathway. Furthermore, the extract can directly inhibit Fusarium oxysporum colony expansion, conidia production, and mycelial growth. Extracts derived from spores or hyphae show no significant difference in inducing disease resistance, and the raw materials are flexible and easy to industrialize. This extract is derived from the cell wall of the pathogen itself, making it environmentally friendly and free from the risk of chemical pesticide residues. It is suitable for the green control of root rot disease in Rehmannia glutinosa.

The application discloses a caviar polypeptide composition with enhanced immune function, a preparation method, application and preparation, belongs to the technical field of bioactive polypeptides, and comprises at least one polypeptide with an amino acid sequence of RWFPGKPLFWRA, FWKPLRGALFPW or KWRFPGALPWFA and a molecular weight of 1400-1550 Da. The preparation method comprises caviar protein extraction, complex enzymolysis, ultrafiltration separation, chromatography purification and solid-phase synthesis. Animal experiments prove that the polypeptide can significantly enhance cell immunity, humoral immunity, monocyte-macrophage function and NK cell activity, the mechanism is related to TLR2 / TLR4 receptor activation and NF-κB / MAPK signal pathways, the safety is good, and the polypeptide is suitable for development into an immune-enhancing health food or medicine.

This invention belongs to the field of active ingredient extraction and purification technology, specifically a neutral polysaccharide ORP-0 from *Agaricus bisporus* and its applications. The preparation method of this invention includes the following steps: (1) pretreatment; (2) polysaccharide extraction; (3) impurity removal; and (4) separation and purification. This invention obtains a single neutral polysaccharide ORP-0 through defatting pretreatment, ultrasonic-assisted extraction, multiple impurity removal processes, and separation and purification using a DEAE-52 cellulose chromatography column. The method of this invention is simple to operate, has mild reaction conditions, and a complete impurity removal process. The obtained neutral polysaccharide has high purity, with a total sugar content of 92.09%. Furthermore, the obtained neutral polysaccharide ORP-0 enhances the activity of RAW 264.7 macrophages, increases the release of immune factors, enhances the expression of phosphorylated proteins in the MAPK signaling pathway, and activates the body's immune response.

The present application relates to the technical field of genetic engineering, and particularly relates to long-chain RNA Lnc_012227 for inhibiting ovary transmission of Salmonella enteritidis and application of the long-chain RNA Lnc_012227 in preventing and controlling Salmonella enteritidis infection.A long-chain RNA Lnc_012227 for inhibiting ovary transmission of Salmonella enteritidis.The Lnc_012227 provided by the present application can indirectly regulate expression of MAP3K8, activate NF-kappa B and MAPK signaling pathways, and enhance inflammatory response of a host, so as to control S.Enteritidis infection.This finding not only provides new molecular level understanding for understanding infection mechanism of Salmonella in duck bodies, but also provides a potential target for developing a new treatment strategy, and is helpful for reducing ovary infection of Salmonella and duck egg pollution caused by Salmonella.

The invention relates to the technical field of biological medicine, in particular to application of TOMM40 in preparation of a medicine for treating breast cancer. The invention finds that TOMM40 overexpression promotes the increase of the content of DDR1 in lipid rafts instead of early-stage endosomes; a co-immunoprecipitation experiment shows that TOMM40 and PHB2 interact with DDR1 and SRC, and DDR1 and SRC also interact with each other; the combination of TOMM40 and PHB2 can promote phosphorylation activation of DDR1, the activated DDR1 further promotes activation of SRC interacting with the activated DDR1, activation of a downstream MAPK signal channel is caused, and meanwhile, the activated DDR1 can directly activate an AKT / mTOR channel; furthermore, the invention finds that the killing ability of tumor cells can be obviously enhanced by further utilizing Flurizoline and DDR1-IN-1 to treat the breast cancer cells, and the method is expected to become a new strategy for breast cancer treatment.

The application discloses a benzofuran derivative, which has a structure shown in formula (I), and discloses a pharmaceutical composition and application in preparation of anti-inflammatory drugs. The application can effectively inhibit LPS-induced inflammation in vivo and in vitro, and can play an anti-inflammatory role by inhibiting the release of inflammatory factors TNF-alpha and IL-6 through inhibition of NF-kappa B and MAPK signal pathways.

The invention belongs to the technical field of biological medicine and pharmacology, and particularly relates to EGCG-5-HT binary oxidation self-agglutination nanoparticles as well as a preparation method and application of the EGCG-5-HT binary oxidation self-agglutination nanoparticles. The EGCG (epigallocatechin gallate)-5-HT binary oxidation auto-agglutination nanoparticles disclosed by the invention are obtained by carrying out oxidation auto-agglutination on EGCG and 5-HT in an alkaline environment. The total concentration of the EGCG and the 5-HT in the reaction liquid is 1.0 to 3.0 mg / mL. The nanoparticles provided by the invention have an anti-oxidation effect, and can inhibit pyroptosis and regulate and control a cell cycle; an NF-kappa B signal channel is inhibited, and the anti-inflammatory effect is achieved; an MAPK signal channel is activated, and cell apoptosis is inhibited; a PI3K-Akt signal channel is activated, and cell proliferation and mucous membrane repair are promoted. When the compound is applied to preparation of IBD medicines, multi-mechanism synergistic treatment of anti-inflammatory, anti-oxidation and mucous membrane repair of IBD is realized; the invention also provides a preparation method of the nanoparticle, and the preparation method is mild in condition and simple.

The invention provides a water-based surfactant preparation for relieving atopic dermatitis and application, and belongs to the field of external preparation development. The active ingredient of the aqueous surfactant preparation is an anionic surfactant for inhibiting an STAT3 signal. NF-kappa B and MAPK signal channels are indirectly inhibited by inhibiting STAT3 activation, and expression of inflammatory factors is remarkably reduced. Compared with a traditional surfactant SLS, the water-based surfactant preparation does not affect cell activity, shows good anti-inflammatory activity in vivo and in vitro, has the advantages of relieving atopic dermatitis skin lesion, reducing serum IgE level, relieving mast cell infiltration and the like, and provides a safer cleaning or external anti-inflammatory choice for AD patients. Therefore, the traditional surfactant is utilized to relieve the inflammation of atopic dermatitis, and meanwhile, the problem that the traditional surfactant irritates skin and aggravates inflammatory response is avoided.

The invention belongs to the technical field of medicines, and particularly relates to application of traditional Chinese medicine active ingredients in antianaphylaxis, in particular to application of rare ginsenoside Rh1 in preparation of medicines for preventing or treating anaphylaxis. According to the invention, the action mechanism of Rh1 in resisting anaphylaxis is systematically clarified by integrating network pharmacology, molecular docking, molecular dynamics simulation and transcriptomics technologies for the first time. The Rh1 acts on four key host targets, namely ALB, CASP3, NFKB1 and STAT3 at the same time, regulates and controls an MAPK signal channel, a Th17cell diffusion channel and a PI3K-Akt signal channel, and synergistically exerts the dual effects of inhibiting allergens from invading host cells and relieving cytokine storm. The Rh1 and the four key targets all have high affinity binding. The invention provides a brand new theoretical basis and a clear mechanism support for developing Rh1-based broad-spectrum, high-efficiency and low-toxicity anti-anaphylaxis drugs.

The invention is applicable to the technical field of biological medicines, and provides application of targeted CHAF1B in preparation of a medicine for regulating and controlling autophagy activity of breast cancer cells. The invention reveals that targeted CHAF1B can activate autophagic death of breast cancer cells for the first time, provides a new strategy for molecular targeted therapy of breast cancer, and shows a good anti-tumor effect; the CHAF1B is proved to be remarkably and highly expressed in breast cancer tissues and is related to prognosis of patients, so that the CHAF1B can be used as a potential diagnosis, treatment and prognosis monitoring target of the breast cancer; the invention discusses that CHAF1B targeted MAPK signal channel induces autophagic death, provides theoretical support for application of CHAF1B as a new therapeutic target, enriches cognition of CHAF1B for regulating breast cancer cell proliferation molecular mechanism, provides a new thought and direction for searching for a new target for breast cancer treatment, and provides a new foundation for application of CHAF1B targeted MAPK signal channel induced autophagic death and application of CHAF1B targeted MAPK signal channel induced autophagic death. And a theoretical basis and an experimental basis are provided for clinically developing a new treatment target.

The invention relates to the technical field of biology, in particular to a TLR2 / TLR4 activating peptide-based CAR-T cell as well as a preparation method and application thereof. Through lentiviral vector transduction, the T cell co-expresses the following components: a) a mesothelin-targeted chimeric antigen receptor CAR; and b) an exogenous oligopeptide EEIYEEFA (SEQ ID NO: 1), which is used for up-regulating downstream NF-kappa B and MAPK signal channels by activating TLR2 / TLR4 so as to further improve the secretion levels of IFN-gamma, IL-2 and GranzymeB (P is less than 0.01). The invention has the advantages that: a T cell TLR2 / TLR4 signal channel is activated by secreting PEP, and M2 type macrophages are polarized into M1 type macrophages, so that the solid tumor treatment effect is obviously enhanced. The cell inhibits tumor growth by 70% in a lung cancer tumor-bearing model, prolongs the lifetime of mice to 45 days, and has important clinical application value.

This invention discloses a sustained-release membrane for postoperative treatment of diabetic peripheral neuropathy and its preparation method. The sustained-release membrane comprises, from the outside in, a PLGA nanofiber outer layer containing tacrolimus and magnesium hydroxide nanoparticles, a glucose-responsive hydrogel middle layer containing insulin and glucose oxidase / catalase, and a PCL-oriented nanofiber inner layer containing methylcobalamin. The layers are connected by a polydopamine interface layer, and the outermost surface of the outer layer is coated with a hyaluronic acid anti-adhesion coating. Insulin, as a local neurotrophic factor, directly activates the PI3K / Akt / mTOR and ERK / MAPK signaling pathways, promoting axonal regeneration and myelin repair. The sustained-release membrane integrates three major functions: immunomodulation / anti-inflammation, glucose-responsive insulin neurotrophic delivery, and sustained nerve regeneration promotion. It prevents postoperative nerve re-adhesion through a spatiotemporal sequential drug release strategy. All components are biodegradable and do not require secondary surgery for removal.

The present application relates to a kind of drug based on PARM1 regulation treatment calcified aortic valve disease and its application.The present application first finds that PARM1 is significantly increased in the aortic valve of calcified aortic valve disease (CAVD) patient, and plays a key role in the osteogenic differentiation process of valve interstitial cells (VICs), and the expression level of PARM1 is knocked down can inhibit the osteogenic differentiation of VICs and extracellular calcium salt deposition, reduce aortic valve calcification, and its mechanism of action involves MAPK signal pathway.The present application provides a new target and treatment idea for the treatment of CAVD, and can be applied to related drug research and development and treatment method development.

The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same. Activation of the p42 / 44 MAPK signaling pathway, including mitogen-activated protein kinase / extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK, has been implicated in the etiology and progression of various cancers. The MEK-ERK pathway is often activated by mutations in the upstream factors BRAF or Ras, or by signals from structurally activated cell surface receptors. Inhibition of MEK may be a promising strategy for controlling the growth of tumors, such as tumors associated with MEK pathway signaling.